Immix Biopharma, Inc.

Healthcare

NASDAQ:IMMX · NASDAQ Capital Market

Market Cap $459.70M Beta 0.10 P/E (TTM) -9.2

$8.45 +4.32%

+$0.35 today

52W Low $1.94High $11.61

Vol 1.09M · Avg 1.02M

EPS (TTM)-$0.91

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+259.57%

Period High

$11.12

Period Low

$1.96

Latest

$8.45

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

$266.95M

MacroGenics, Inc.

NASDAQ:MGNX

$251.71M

Whitehawk Therapeutics Inc

NASDAQ:WHWK

$205.72M

Surrozen, Inc.

NASDAQ:SRZN

$174.90M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

$158.38M

Coya Therapeutics, Inc.

NASDAQ:COYA

$86.31M

Oncolytics Biotech Inc.

NASDAQ:ONCY

$80.59M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

$69.97M

Instil Bio, Inc.

NASDAQ:TIL

$53.71M

Atossa Therapeutics, Inc.

ATOS

$21.18M

What is the latest IMMX filing?

The latest filing shown is SC 13G/A dated Jun 5, 2026.

How many recent filings does IMMX have?

Intrinsic Alpha currently shows 20 recent filings for IMMX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.